Last reviewed 2026-04-20 · How we verify

Slynd (DROSPIRENONE)

Slynd works by binding to the mineralocorticoid receptor, a protein that plays a role in hormone regulation.

Slynd (DROSPIRENONE) is a small molecule progestin developed by Exeltis USA Inc, targeting the mineralocorticoid receptor. It is FDA-approved for various indications including acne, contraception, and menopausal symptoms. Slynd has a half-life of 30 hours and 76% bioavailability. Currently, it is patented and has no generic manufacturers. Key safety considerations include its potential effects on blood pressure and lipid profiles.

At a glance

Mechanism of action

SLYND progestin-only oral contraceptive lowers the risk of becoming pregnant primarily by suppressing ovulation.

Approved indications

• Acne vulgaris
• Atrophic vaginitis
• Atrophic vulva
• Contraception
• Controlled ovarian stimulation
• Dysmenorrhea
• Menopausal flushing
• Premenstrual dysphoric disorder

Boxed warnings

• WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs should not be used by women who are over 35 years of age and smoke [see Contraindications ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. • Women over 35 years old who smoke should not use Yaz ( 4 ). • Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 4 )

Common side effects

• acne
• metrorrhagia
• headache
• breast pain
• weight increased
• dysmenorrhea
• vaginal hemorrhage
• libido decreased
• breast tenderness
• menstruation irregular
• nausea

Key clinical trials

• Anxiety and Depression in Adolescent PCOS (NA)
• Pharmacokinetics of Drospirenone Only Pills: A Pre- and Post-Bariatric Surgery Study (PHASE1,PHASE2)
• Drospirenone Only Pills and Cervical Mucus Changes: A Pre- and Post-Bariatric Surgery Study (NA)
• A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
• Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
• Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
• A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
• Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (NA)

Patents

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.